Overcoming Barriers

Delivering Hope

a molecular solution to address unmet medical needs and rethink drug development


Accessing sustainable pipeline growth through N1 delivery platform

Transforming Previous R&D Loss into Gold Mine for Drug Development

About N1 Life

N1 Life, Inc. is a biopharma company founded at Stanford  in 2019. The company focuses on the early development (preclinical to early clinical) of new therapeutics using its barrier-penetrating delivery platform. The N1 delivery technology enables a fast-path strategy to the clinic and consumer market by maximizing the benefit of known drugs/drug candidates and existing data, and accessing the previously undruggable space.

N1 Life is creating an innovative and sustainable model consisting of therapeutic pipeline, screening service, and consumer product program.


Our Technology

N1 Delivery Platform

N1 Life develops new therapeutic candidates by learning from preclinical and clinical data of existing drugs or drug candidates, and maximizing their advantages through the innovative N1 delivery technology.

Rethink drug development

Rescue drug failures

Reinvestigate  existing data

Recover sunk R&D cost


N1 Team:

The Core of Innovation


Xiaoyu Zang, PhD (Janice)

Founder, CEO & President


PhD in Chemistry from Stanford University. Passionate scientist entrepreneur with focus on drug delivery technologies using peptide, protein, polymer for small molecule drugs and biologics. Inventor of 2 Stanford patents.


Lin Cheng, PhD

VP of Chemistry

20 years industry experience in new drug discovery, drug delivery, polymer-drug conjugation, medicinal chemistry and polymer chemistry.  Involved in programs that generated novel compounds from preclinical candidates to FDA approved drugs in therapeutic areas including immuno-oncology, inflammation, pain, HIV and renal diseases. Inventor of Movantik, an FDA approved oral peripherally acting mu-opioid receptor antagonist (PAMORA) medicine.


Faye Hsieh, PhD


20+ years in pharmaceutical industry.  Highly motivated with extensive experience in pharmacokinetics, ADME and strategic inputs to guide drug discovery, preclinical and clinical development and IND filing.  Held senior positions at Amgen and Nektar Therapeutics. 


Shawn Lee, PhD

Executive Chairman

CEO & President of CPC Scientific. 30+ years’ industry experience in peptide manufacturing and peptide drug development


Paul A. Wender, PhD


Director of Advisory Board

Bergstrom Professor of Chemistry and chemical and system biology at Stanford University, elected member of National Academy of Sciences,  American Academy of Arts & Sciences


Ke Jiang, PhD


Over 10 years’ experience in pharmaceutical chemistry and peptide chemistry. Experienced in organic synthesis, peptide synthesis, peptide-small molecule conjugation, LC-MS, and HPLC.


Esther Chung

Legal Counsel & Operation Advisor

CA & NY Bar.

Held various executive positions (business and legal) at a startup that raised over $21M from a top tier VC and won global awards for its product. W as a senior attorney at Orrick, Herrington & Sutcliffe LLP, working with investments in then pre-IPO startup companies like Financial Engines (NASDAQ: FNGN), Trulia (NYSE: TRLA) and LinkedIn (NYSE: LNKD).  


N1 Life PipeLine Program

Coming Soon

Contact N1 Life, Reach More Possibility of Life

Thanks for submitting!

We will be in touch!